Full Press Release Details
OncoGenex Announces Reduction in Force to Extend Cash Runway and Align
Operations with Clinical Development Priorities
BOTHELL Wash. And VANCOUVER, British Columbia, February 4, 2016 OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it is
implementing a plan to reduce operating expenses, including a workforce reduction of approximately 27%. The Company expects cost savings associated with the reduction of employees and consultants, together with the elimination of certain planned
expenditures not required for the completion of ongoing trials, will extend cash runway into the third quarter of 2017.
OncoGenex will remain focused on
executing clinical development plans in order to reach several near-term milestones for both the custirsen and apatorsen programs.
31, 2015, the Company s cash, cash equivalents and short-term investments were $55.2 million. Based on current expectations, the Company believes that resources will be sufficient to fund currently planned operations into the third quarter of
2017. Depending on timing of enrollment or event-driven final analyses, the expected timing of key milestones and activities are as follows:
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer
patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. Custirsen is currently in Phase 3 clinical development as a
treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More
information is available at www.OncoGenex.com and at the company s Twitter account: https://twitter.com/OncoGenex_IR.
OncoGenex Forward Looking Statements
release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the use and adequacy of cash reserves, statements
regarding timing for clinical trial milestones and statements regarding the potential benefits and potential development of our product candidates. All statements other than statements of historical fact are statements that could be deemed
forward-looking statements. These statements are based on management s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those
described in the forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, among others, the risk of delays in our expected clinical trials, the risk that new developments in the rapidly evolving
cancer therapy landscape require changes in our clinical trial plans or limit the potential benefits of our product, the risk that we are unable to raise on acceptable terms the capital needed to complete our clinical trials, the risk that our
product candidates do not demonstrate the hypothesized or expected benefits and the other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including the Company s
Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be
required by applicable law.